Avid Bioservices Inc (CDMO)

[djohn]

http://www.scribd.com/doc/59691852/45/What-does-the-future-hold
Table 4.3 on PAGE 75

Table 4.3 – The most promising new therapeutical options for CHC(as of June 2011) *CategoryMechanismExampleManufacturerPhaseBI201335BoehringerIIITMC435Medivir/TibotecIIIGS-9256, -9451GileadIIDanoprevirIntermune/RocheIIVaniprevirMerckIINS3/NS4AproteaseinhibitorsACH-1625Achillon Pharm.IIABT 450Abbott/EnantaIIBMS-650032Bristol-Myers SquibbIIaMericitabineRoche/PharmasetIIPSI-7977PharmasetIIIDX 184IdenixIINS5B polymeraseinhibitors,nucleosideanalogsFilibuvirPfizerIIGS-9190GileadIIVX 222VertexIIABT 333, -072AbbottIISetrobuvirAnadys Pharm.IINS5B polymeraseinhibitors,non-nucleosideanalogsBMS-790052Bristol-Myers SquibbIIABT 267AbbottIIAZD 7295AstraZenecaIIDirect-actingantiviralsNS5A inhibitorsCyclophilinsinhibitorsAlisporivirNovartis/DebiopharmIIIMBL-HCV1humanmonoclonalantibodyThe University of Massachusetts MedicalSchoolIIVirus entryinhibitorsITX 5061iTherXIIHosttargetingagentsBavituximabPeregrine Pharm.II* For more information, seehttp://hcvdrugs.com/and the manufacturers' web sites presented at the end of the chapter.